Ionizing radiation induces expression and binding activity of the nuclear factor kBBRACH, M. A; HASS, R; SHERMAN, M. L et al.The Journal of clinical investigation. 1991, Vol 88, Num 2, pp 691-695, issn 0021-9738Article

HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanomaZUBOVITS, Judit; BUZNEY, Elizabeth; YU, Lawrence et al.Human pathology. 2004, Vol 35, Num 2, pp 217-223, issn 0046-8177, 7 p.Article

SERIAL COMPLEMENT MEASUREMENTS IN PATIENTS WITH LEUKAEMIADO QUANG MINH; CZINK E; MOD A et al.1983; CLINICAL AND LABORATORY HAEMATOLOGY; ISSN 0141-9854; GBR; DA. 1983; VOL. 5; NO 1; PP. 23-34; BIBL. 2 P.Article

LES CONCENTRATIONS PLASMATIQUES DES IMMUNOGLOBULINES ET DU C3 CHEZ LES CANCEREUX.CAPPELAERE P; GRANIER AM; VANLERENBERGHE J et al.1977; LILLE MED.; FR.; DA. 1977; VOL. 22; NO 8; PP. 533-542; BIBL. 2 P.Article

HODGKIN'S DISEASE ASSOCIATED WITH UNUSUAL IMMUNOLOGICAL MANIFESTATIONSMIRO JM; GATELL JM; LLEBARIA C et al.1982; NOUV. REV. FR. HEMATOL.; ISSN 0029-4810; FRA; DA. 1982; VOL. 24; NO 2; PP. 81-83; ABS. FRE; BIBL. 19 REF.Article

DEMONSTRATION OF C3 RECEPTORS ON FROZEN SECTIONS OF NORMAL LYMPHOID TISSUE AND MALIGNANT LYMPHOMAS USING VARIOUS EAC COMPLEXESSTEIN H; GROSSKOPF E; LENNERT K et al.1980; BLUT; DEU; DA. 1980; VOL. 41; NO 2; PP. 101-118; ABS. GER; BIBL. 24 REF.Article

COMPLEMENT RECEPTOR B LYMPHOCYTES IN NODULAR SCLEROSING HODGKIN'S DISEASE.COSSMAN J; DEEGAN MJ; SCHNITZER B et al.1977; CANCER; U.S.A.; DA. 1977; VOL. 39; NO 5; PP. 2166-2173; BIBL. 36 REF.Article

Photodynamic therapy-generated vaccine for cancer therapyKORBELIK, Mladen; JINGHAI SUN.Cancer immunology and immunotherapy. 2006, Vol 55, Num 8, pp 900-909, issn 0340-7004, 10 p.Article

CAPPING OF PERIPHERAL BLOOD LYMPHOCYTE C3 RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA: RELATIONSHIP TO CHEMOTHERAPYGORMUS BJ; BASARA ML; OKEN MM et al.1981; INT. J. CANCER; ISSN 0020-7136; CHE; DA. 1981; VOL. 27; NO 2; PP. 151-159; BIBL. 31 REF.Article

INFECTIONS COMPLICATIONS AND HOST IMMUNE DEFENSE IN ACUTE LEUKEMIANEDELKOVA M; BACALOVA S; GEORGIEVA B et al.1981; EUR. J. CANCER; ISSN 0014-2964; GBR; DA. 1981; VOL. 17; NO 6; PP. 617-622; BIBL. 36 REF.Article

ABSENCE OF A RECEPTOR FOR FIXED C3 ON THE HAIRY CELLS OF LEUKAEMIC RETICULOENDOTHELIOSIS.BURNS GF; CAWLEY JC; BARKER CR et al.1977; CLIN. EXPER. IMMUNOL.; G.B.; DA. 1977; VOL. 29; NO 3; PP. 442-446; BIBL. 28 REF.Article

ACTIVATION OF THE ALTERNATIVE PATHWAY OF COMPLEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA.KALWINSKY DK; URMSON JR; STITZEL AE et al.1976; J. LAB. CLIN. MED.; U.S.A.; DA. 1976; VOL. 88; NO 5; PP. 745-756; BIBL. 1 P. 1/2Article

SERUM I-K (IMMUNOCONGLUTININS) IN HODGKIN'S DISEASEMARUCCI P; ABBOLITO MR; BARDUAGNI A et al.1975; BIOMEDICINE; FR.; DA. 1975; VOL. 23; NO 2; PP. 52-54; ABS. FR.; BIBL. 19REF.Article

C3b receptor (CR1) on erythrocytes in various diseasesTAKEMURA, S; DEGUCHI, M; UEDA, M et al.Immunology letters. 1984, Vol 7, Num 6, pp 325-328, issn 0165-2478Article

Interactions des cellules du système immunitaire avec la voie alterne du complément = Interaction of immune system cells with the alternative complément pathwayPRAZ, Françoise.1983, 105 fThesis

Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomasANDOH, A; FUJIYAMA, Y; SAKUMOTO, H et al.Clinical and experimental immunology (Print). 1998, Vol 111, Num 3, pp 477-483, issn 0009-9104Article

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanismsHUH, Jung-Im; CALVO, Alfonso; STAFFORD, Jeffrey et al.Oncogene (Basingstoke). 2005, Vol 24, Num 5, pp 790-800, issn 0950-9232, 11 p.Article

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestineHUBER, Samuel; GAGLIANI, Nicola; VALENZUELA, David M et al.Nature (London). 2012, Vol 491, Num 7423, pp 259-263, issn 0028-0836, 5 p.Article

IL-22 : A critical mediator in mucosal host defenseAUJLA, S. J; KOLLS, J. K.Journal of molecular medicine (Berlin. Print). 2009, Vol 87, Num 5, pp 451-454, issn 0946-2716, 4 p.Article

COMPLEMENT RECEPTOR SUBTYPES C3B AND C3D IN LYMPHATIC TISSUE AND FOLLICULAR LYMPHOMA.STEIN H; SIEMSSEN U; LENNERT K et al.1978; BRIT. J. CANCER; G.B.; DA. 1978; VOL. 37; NO 4; PP. 520-529; BIBL. 1 P. 1/2Article

DIFFERING SURFACE MARKER CHARACTERISTICS IN PLASMA CELL DYSCRASIAS WITH PARTICULAR REFERENCE TO IGM MYELOMA.BURNS GF; CAWLEY JC; BARKER CR et al.1978; CLIN. EXPER. IMMUNOL.; G.B.; DA. 1978; VOL. 31; NO 3; PP. 414-418; BIBL. 19 REF.Article

Diagnostic value of ferritin, haptoglobin, α₁-antitrypsin, lactate dehydrogenase and complement factors C3 and C4 in pleural effusion differentiationALEXANDRAKIS, M; COULOCHERI, S; KYRIAKOU, D et al.Respiratory medicine. 1997, Vol 91, Num 9, pp 517-523, issn 0954-6111Article

Increased intratumoral IL-22-producing CD4⁺ T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survivalYUAN ZHUANG; PENG, Liu-Sheng; PING LUO et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 11, pp 1965-1975, issn 0340-7004, 11 p.Article

Welche Kältemittel in der Zukunft? = Which refrigerant in the future?DOÊRING, R.Die Kälte und Klimatechnik. 1990, Vol 43, Num 9, pp 472-482, issn 0343-2246, 6 p.Article

CIRCULATING IMMUNE COMPLEXES, COMPLEMENT AND COMPLEMENT COMPONENT LEVELS IN CHILDHOOD HODGKIN'S DISEASEBRANDEIS WE; TAN C; WANG Y et al.1980; CLIN. EXPER. IMMUNOL.; GBR; DA. 1980; VOL. 39; NO 3; PP. 551-561; BIBL. 31 REF.Article